117 related articles for article (PubMed ID: 38336557)
21. Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.
Lee YC; Lin SC; Kim Y
Cureus; 2021 Jun; 13(6):e15980. PubMed ID: 34336471
[TBL] [Abstract][Full Text] [Related]
22. Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for (125)I brachytherapy.
Karlsson M; Nilsson J; Lundell M; Carlsson Tedgren A
Brachytherapy; 2014; 13(6):651-6. PubMed ID: 24950821
[TBL] [Abstract][Full Text] [Related]
23. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
Melhus CS; Rivard MJ
Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
[TBL] [Abstract][Full Text] [Related]
24. Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors.
McCauley Cutsinger S; Forsman R; Corner S; Deufel CL
Brachytherapy; 2019; 18(6):890-897. PubMed ID: 31444131
[TBL] [Abstract][Full Text] [Related]
25. Update of the CLRP eye plaque brachytherapy database for photon-emitting sources.
Safigholi H; Parsons Z; Deering SG; Thomson RM
Med Phys; 2021 Jun; 48(6):3373-3283. PubMed ID: 33735471
[TBL] [Abstract][Full Text] [Related]
26. Validation of Monte Carlo dose calculations near 125I sources in the presence of bounded heterogeneities.
Das RK; Keleti D; Zhu Y; Kirov AS; Meigooni AS; Williamson JF
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):843-53. PubMed ID: 9240654
[TBL] [Abstract][Full Text] [Related]
27. Improved treatment planning for COMS eye plaques.
Astrahan MA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
[TBL] [Abstract][Full Text] [Related]
28. Monte Carlo investigation of dose distribution of uniformly and non-uniformly loaded standard and notched eye plaques.
Semeniuk O; Malkov V; Chamberland MJP; Weersink RA
J Appl Clin Med Phys; 2023 Dec; 24(12):e14149. PubMed ID: 37738654
[TBL] [Abstract][Full Text] [Related]
29. ROPES eye plaque brachytherapy dosimetry for two models of (103)Pd seeds.
Saidi P; Sadeghi M; Shirazi A; Tenreiro C
Australas Phys Eng Sci Med; 2011 Jun; 34(2):223-31. PubMed ID: 21452056
[TBL] [Abstract][Full Text] [Related]
30. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.
Lesperance M; Inglis-Whalen M; Thomson RM
Med Phys; 2014 Feb; 41(2):021717. PubMed ID: 24506608
[TBL] [Abstract][Full Text] [Related]
31. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
[TBL] [Abstract][Full Text] [Related]
32. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
Johnson JE; Deufel CL; Furutani KM
Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
[TBL] [Abstract][Full Text] [Related]
33. Analysis of dose to the macula, optic disc, and lens in relation to vision toxicities - A retrospective study using COMS eye plaques.
Oare C; Sun S; Dusenbery K; Reynolds M; Koozekanani D; Gerbi B; Ferreira C
Phys Med; 2022 Sep; 101():71-78. PubMed ID: 35981450
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
[TBL] [Abstract][Full Text] [Related]
35. Dose characteristics of Au-198 eye brachytherapy applicator: A Monte Carlo study.
Kamrani S; Aghamiri SMR; Hashemi S
Appl Radiat Isot; 2021 Oct; 176():109866. PubMed ID: 34293507
[TBL] [Abstract][Full Text] [Related]
36. Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy.
Thomson RM; Furutani KM; Pulido JS; Stafford SL; Rogers DW
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1261-9. PubMed ID: 20472360
[TBL] [Abstract][Full Text] [Related]
37. Monte Carlo dosimetry for I125 and Pd103 eye plaque brachytherapy.
Thomson RM; Taylor REP; Rogers DWO
Med Phys; 2008 Dec; 35(12):5530-5543. PubMed ID: 28525130
[TBL] [Abstract][Full Text] [Related]
38. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric characteristics, air-kerma strength calibration and verification of Monte Carlo simulation for a new Ytterbium-169 brachytherapy source.
Perera H; Williamson JF; Li Z; Mishra V; Meigooni AS
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):953-70. PubMed ID: 8138449
[TBL] [Abstract][Full Text] [Related]
40. Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience.
Meltsner SG; Rodrigues A; Materin MA; Kirsch DG; Craciunescu O
J Appl Clin Med Phys; 2023 May; 24(5):e13902. PubMed ID: 36637797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
